Ferring is committed to the future of urologic oncology treatment

Together we’re entering a new phase in the treatment of bladder cancer, exploring new therapies to support the unique needs of your patients.

philosophy-imageThe new Ferring Oncology division

In the US, approximately 80,000 people are diagnosed with bladder cancer annually1.

Ferring is building its US Oncology team in preparation to commercialize nadofaragene firadenovec (rAd-IFNa2b), a novel gene-mediated therapy in Phase 3 development to potentially treat high-grade non-muscle invasive bladder cancer (NMIBC) patients, who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The US FDA has granted Fast Track and Breakthrough Therapy designation for nadofaragene firadenovec.

See current job openings


This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience.

©2008-2019 Ferring Pharmaceuticals.  US-1900006